GSK-257049

Curevo's shingles vaccine candidate amezosvatein has demonstrated strong immunogenicity with improved tolerability in Phase 2 studies, positioning it as a potential alternative to current market options.

The U.S. Food and Drug Administration has imposed a clinical hold on BioNTech's investigational malaria vaccine trial, temporarily halting the study's progression.

A significant advancement in malaria vaccine research has been achieved with the validation of a multiplexed immunoassay for the R21/MM vaccine. This assay, capable of simultaneously measuring antibody responses to multiple antigens, has shown high efficacy in clinical trials across Sub-Saharan Africa, offering new hope in the fight against malaria.

A Phase IIb trial of the RH5.1/Matrix-M vaccine shows 55% efficacy in preventing clinical malaria over six months in young children.

A phase 2b trial in Burkina Faso demonstrates the RH5.1/Matrix-M malaria vaccine's safety and efficacy, showing a 55% vaccine efficacy in a delayed third-dose regimen among children aged 5-17 months.